Government Accountability Office says in its report that FDA is lacking a clear and effective process to upheld decisions. It is making management lapse of post market drug safety issues.
A federal investigation has criticized the Food and Drug Administration’s monitoring of drugs on the U.S. market. It has said that the agency must have more power to order drug companies to conduct safety trials on their products. The FDA now lacks that explicit authority. Although officials have said that the extra power could help them.
The agency and drug manufacturers have resisted those calls. The agency established a new drug safety board. It is in the wake of the removal of Vioxx and Pfizer`s Bextra from pharmacy shelves.
Read